BERLIN–(BUSINESS WIRE)–Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that pursuant to the liquidity contract entrusted to Invest Securities by TME Pharma N.V. the assets outlined below appeared on the liquidity account. The following assets appeared on the liquidity account as of December 31, 2023: Number of shares: 35,658 Cash
Business Wire Stock Sale/Buyback News
